Studienlage · Detail
Klarer Nutzen
GRADE
Niedrig
23 Zitate
Stichproben = 2.183 Pat.
DauerQuerschnittsstudie
EndpunktSF-36
Verblindungn.a.
DesignKohortenstudie
Cannabinoidvollspektrum
Kernaussage
Patienten berichteten Verbesserungen in Bereichen Körperschmerz, physische Funktionsfähigkeit und soziale Funktionsfähigkeit nach Initiierung von medizinischem Cannabis; 79% zeigten Reduktion oder Beendigung der Opioidmedikamentation.
Zusammenfassung
Befragung medizinischer Cannabis-Patienten zu selbstberichteten Verbesserungen in Gesundheitsfunktionen und Opioid-Reduktion; Real-World-Daten, aber ohne kontrolliertes Design oder objektive Opioid-Verbrauchsmessung.
P
PopulationErwachsene medizinische Cannabis-Patienten in Florida, n=2.183, überwiegend 20-70 Jahre, 54% weiblich, häufigste Indikationen: Schmerz+Psychische Erkrankungen (48%), Psychische Erkrankungen (29%), Schmerz (9%)
I
InterventionMedizinisches Cannabis (verschiedene Applikationsformen aus Dispensaries)
O
Outcome61% berichteten vorherige Opiat-Nutzung, davon 79% Reduktion/Cessation nach Cannabis-Initiation; Verbesserungen in SF-36-Domänen (Schmerz, körperliche/soziale Funktion), keine Verschlechterung der Lebensqualität
Vertrauen in die Evidenz
Niedrig
Zweite von vier GRADE-Stufen, die Effektschätzung ist begrenzt verlässlich.
Qualitätsprofil
Größe
★★★★★
Verblindung
—
Effektstärke
Klarer Nutzen
Zitate / Jahr
★★★★★
Autoren
Teilen
Abstract
Purpose: Opioid use rates have dropped as North American patients gain access to medical cannabis, indicating a harm reduction role, yet health outcomes remain mostly unexplored. This study presents self-reported medical cannabis use, perceptions of health functioning, and changes in opioid pain medication use in Florida medical cannabis patients.Methods: Patients (n = 2,183) recruited from medical dispensaries across Florida completed a 66-item cross-sectional survey that included demographic, health, and medication usage items, along with items from the Medical Outcomes Survey (SF-36) to assess health functioning before and after cannabis initiation.Results: Most participants were between the ages of 20 and 70 years of age (95%), over 54% were female, 47% were employed, and most (85%) were white. Commonly reported ailment groups were Pain and Mental Health combined (47.92%), Mental Health (28.86%) or Pain (9.07%). Health domains of bodily pain, physical functioning, and social functioning improved while limitations due to physical and emotional problems were unchanged. Most patients rated medical cannabis as being important to their quality of life. Many (60.98%) reported using pain medications prior to medical cannabis, 93.36% of these reported a change in pain medication after medical cannabis. The majority of participants (79%) reported either cessation or reduction in pain medication use following initiation of medical cannabis and 11.47% described improved functioning.Conclusions: The findings suggest that some medical cannabis patients decreased opioid use without harming quality of life or health functioning, soon after the legalization of medical cannabis. The public health implications of medical cannabis as an alternative pain medication are discussed.
„Was dem Handeln im Weg steht, wird zum Weg.“